SVQ Sinovac Biotech Ltd.

INVESTOR LOSS ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sinovac Biotech Ltd. - SVA

NEW YORK--(BUSINESS WIRE)--

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ: SVA) resulting from allegations that Sinovac may have issued materially misleading business information to the investing public.

On December 21, 2016, an article published on SeekingAlpha.com revealed that according to a recent Beijing court judgment, the Chairman and CEO of Sinovac, Weidong Ying, paid bribes to Yin Hongzhang, the Deputy Director General of the Center for Drug Evaluation for the China Food and Drug Administration, and his wife, in order to help advance drug applications and evaluations.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Sinovac investors. If you purchased shares of Sinovac, please visit the firm’s website at http://www.rosenlegal.com/cases-1015.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
21/12/2016

Underlying

SVQSinovac Biotech Ltd.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sinovac Biotech Ltd.

 PRESS RELEASE
Free
SVQ Sinovac Biotech...

September 1st Deadline Alert: The Law Offices of Howard G. Smith Remin...

BENSALEM, Pa.--(BUSINESS WIRE)-- Law Offices of Howard G. Smith reminds investors of the September 1, 2017 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) securities between April 30, 2013 to May 16, 2017, inclusive (the “Class Period”). Sinovac investors have until September 1, 2017 to file a lead plaintiff motion. Investors suffering losses on their Sinovac investments are encouraged to conta...

August 30, 2017 1 EN
 PRESS RELEASE
Free
SVQ Sinovac Biotech...

The Klein Law Firm Reminds Investors of a Class Action Filed on Behalf...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ:SVA) who purchased shares between April 30, 2013 and May 16, 2017. The action, which was filed in District of New Jersey, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Defendant Weidong Yin,...

July 21, 2017 1 EN
 PRESS RELEASE
Free
SVQ Sinovac Biotech...

The Klein Law Firm Announces a Class Action Filed on Behalf of Sinovac...

NEW YORK--(BUSINESS WIRE)-- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Sinovac Biotech Ltd. (NASDAQ: SVA) who purchased shares between April 30, 2013 and May 16, 2017. The action, which was filed in District of New Jersey, alleges that the Company violated federal securities laws. In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (1) Defendant Weid...

July 20, 2017 1 EN
 PRESS RELEASE
Free
SVQ Sinovac Biotech...

SVA INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors ...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in District of New Jersey on behalf of investors who purchased Sinovac Biotech Ltd. ("Sinovac Biotech Ltd.") (NASDAQ:SVA) securities between April 30, 2013 and May 16, 2017. Click here to learn about the case: http://www.wongesq.com/pslra-sb/sinovac-biotech-ltd?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period, the Company issued materially fal...

July 19, 2017 1 EN
 PRESS RELEASE
Free
SVQ Sinovac Biotech...

SVA SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Invest...

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in District of New Jersey on behalf of investors who purchased Sinovac Biotech Ltd. ("Sinovac Biotech Ltd.") (NASDAQ:SVA) securities between April 30, 2013 and May 16, 2017. Click here to learn about the case: http://www.wongesq.com/pslra-sb/sinovac-biotech-ltd?wire=2. There is no cost or obligation to you. According to the complaint, throughout the Class Period, the Company issued materially fal...

July 18, 2017 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch